ARUP's Laboratory Test Directory

8100214: Cytology, SurePath™ Liquid-Based Pap Test (AutoCyte PREP™ System) with Reflex to Human Papillomavirus (HPV) DNA Probe, High Risk

Test Mnemonic: GAR
Methodology: PrepStain™ Slide Processor/Routine Cytopathologic Evaluation/Nucleic Acid Probe

Performed: Mon-Fri

Reported: 1-14 days

Specimen Required:  
Collect: and Transport:  Refer to Cytology, SurePath™ Liquid-Based Pap Test (AutoCyte PREP™ System) Specimen Collection in this section for collection guidelines.

Transport:

Submit specimen according to Biological Substance, Category B, shipping guidelines.

Pediatric Collection/Transport:

Submit specimen according to Biological Substance, Category B, shipping guidelines.

Remarks: This test includes a Cytology, SurePath™Liquid-Based Pap Test (AutoCyte PREP™ System) (8100400) and a Human Papillomavirus (HPV) DNA Probe, SurePath® (Autocyte™) (0060744), ONLY if the SurePath™ Liquid-Based Pap Test is interpreted as atypical squamous cells of undetermined significance (ASC-US).

Unacceptable Conditions: Refer to Unacceptable Conditions for Human Papillomavirus (HPV) DNA Probe, High Risk, SurePath® (Autocyte™) (0060744), and Cytology, SurePath™ Liquid-Based Pap Test (AutoCyte PREP™ System) (8100400).

Stability: Ambient: 1 month; Refrigerated: 1 month; Frozen: Unacceptable

Reference Interval:
High-risk HPV:  Negative

Interpretive Data:
Women with atypical squamous cells of undetermined significance (ASC-US) should be managed using a program of either repeat cervical cytology testing, immediate colposcopy, or DNA testing for high-risk types of Human Papillomavirus (HPV).  Testing for HPV DNA is the preferred approach when liquid-based cytology is used for screening.  All women who test positive for high-risk HPV DNA should be referred for colposcopic evaluation.  Women with ASC-US who test negative for high-risk HPV DNA can be followed up with repeat cytologic testing at 12 months (2001 ASCCP Guidelines -JAMA 2002; 287:2120-2129)

A positive high risk HPV test result indicates that the patient may be infected with one or more of the following HPV genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; which are associated with cervical cancer and its precursor lesions.  However, cross-reactions with other genotypes may occur.  Results should be correlated with cytologic/histologic findings.

The performance characteristics of this test were determined by ARUP Laboratories, Inc.



Note:
A negative result does not rule out the presence of an HPV genotype absent from the test panel, a low level infection, or specimen sampling error.

CPT Code(s):
CPT Codes vary based on testing performed.  If reflexed to HPV add 87621 High Risk HPV